Organisation paid for research Program year 2025 Source: CMS Open Payments

Allergy Asthma and Sinus Center

Neither a doctor nor a teaching hospital

Research payments

$169,320

45 payments

Through program year 2025, Allergy Asthma and Sinus Center is reported as receiving $169,320 in research payments, across 45 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $16,538 1
2023 Research $24,336 13
2022 Research $23,124 4
2021 Research $103,563 26
2020 Research $1,760 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. Teva Pharmaceuticals USA, Inc. $108,192 29 payments
  2. Regeneron Pharmaceuticals, Inc. $44,591 15 payments
  3. Sanofi US Services Inc. $16,538 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $69,094 7 payments
  2. A Randomized, Double-Blind, Placebo-Controlled Study in Cat-Allergic Patients With Allergic Rhinitis Who Live With a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies During Natural Cat Exposure in the Home $44,591 15 payments
  3. CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma $38,569 8 payments
  4. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $16,538 1 payment
  5. A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study to Evaluate the Efficacy and Safety of TEV-48574 in Adults With T2-low/Non-T2 Severe Uncontrolled Asthma $530 14 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record